Trial Condition(s):
Carcinoma, Hepatocellular, Carcinoma, Renal Cell
Regulatory Post Marketing Surveillance Study on Nexavar®
Bayer Identifier:
14792
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar
Inclusion Criteria
- Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar.
Exclusion Criteria
- Exclusion criteria must be read in conjunction with the local product information but patients who are participating in other interventional studies currently will be excluded.
Trial Summary
Enrollment Goal
2845
Trial Dates
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
| Locations | |
|---|---|
Locations Investigative Site Many Locations, South Korea | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
Regulatory Post Marketing Surveillance Study on Nexavar®
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Adverse events collectionTimeframe: From start of treatment to 4 weeks after discontinuation of treatment
Secondary Outcome
- Duration of treatment, dosage and indicationTimeframe: Whole treatment period
- Tumor statusTimeframe: Whole treatment period
- Performance statusTimeframe: Whole treatment period
Additional Information
Copyright © Bayer
Powered by
